Combined oral contraceptive therapy in women with posterior deep infiltrating endometriosis

Mohamed Mabrouk, Frascà C, Clarissa Frascà, E. Geraci, Elisa Geraci, Geraci E, Giulia Montanari, Montanari G, Giulia Ferrini, Ferrini G, Diego Raimondo, Alvisi S, Stefania Alvisi, Paradisi R, Roberto Paradisi, Villa G, Gioia Villa, Renato Seracchioli
Journal of Minimally Invasive Gynecology · 2011 · vol. 18(4) , pp. 470–474 · doi:10.1016/j.jmig.2011.04.008 · PMID:21777836 · W2051207701
Observational OA: closed CC0 ⤵ 38 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This study investigated the effects of combined oral contraceptive therapy on women diagnosed with posterior deep infiltrating endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

STUDY OBJECTIVE: To estimate the effect of combined oral contraceptives (COCs) in women with deep infiltrating endometriosis. DESIGN: Retrospective study (Canadian Task Force classification II-2). SETTING: Tertiary care university hospital. PATIENTS: One hundred six women with uncomplicated posterior deep infiltrating endometriosis scheduled to undergo laparoscopic surgery between November 2004 and November 2009. INTERVENTIONS: During the waiting-list time, between surgical scheduling and laparoscopic intervention (preoperative period), 75 patients received cyclic COCs (users), and 31 received no hormone therapy (COC nonusers). MEASUREMENTS AND MAIN RESULTS: Patients had undergone 2 clinical examinations, at surgical scheduling and immediately before surgery. Presence and intensity of dysmenorrhea, dyspareunia, chronic pelvic pain, and dyschezia were evaluated using a 10-point visual analog scale (VAS) (primary outcome). In both examinations, patients underwent transvaginal ultrasonography to evaluate localization and mean diameter of endometriotic nodules. Quality of life was evaluated using the Short Form-36 (SF-36) score. Mean (SD) nodule diameter at the beginning and end of the preoperative period in COC users was, respectively, 24.81 (15.13) mm and 26.66 (15.5) mm (p = .09), and in the nonuser group was, respectively, 23.09 (11.11) mm and 30.89 (19.1) mm (p = .007). In COC users, VAS scores for dysmenorrhea, dyspareunia, chronic pelvic pain, and dyschezia did not vary significantly during the preoperative period (p = .90, p = .55, p = .15, and p = .17, respectively). In nonusers, VAS scores for dysmenorrhea and dyspareunia were significantly higher at the second examination than at the first examination (p = .002 and p = .005, respectively), whereas scores for chronic pelvic pain and dyschezia did not vary during the preoperative period (p = .88 and p = .16, respectively). The Short Form-36 total score did not vary significantly during the preoperative period in either the COC user group (p = .82) or the nonusers group (p = .76). CONCLUSIONS: Combined oral contraceptive therapy can have a role in restraining the progression of dysmenorrhea and dyspareunia and the growth of deep endometriotic nodules.

My notes (saved in your browser only)

Condition tags

endometriosisdie_deep_infiltrating

MeSH descriptors

Contraceptives, Oral, Combined Endometriosis Adult Adult Contraceptives, Oral, Combined Contraceptives, Oral, Combined Endometriosis Endometriosis Endometriosis Female Female Humans Humans Preoperative Care Preoperative Care Retrospective Studies Retrospective Studies

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (25)

Cited by (37)

Source provenance

europepmc
last seen: 2026-10-13T06:10:10.580696+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:09:10.644269+00:00
License: CC0 · commercial use OK